REGENXBIO (RGNX) reported new, positive interim data from two additional patients in the Phase I/II portion of the AFFINITY DUCHENNE trial of RGX-202, a differentiated investigational gene therapy ...

"RGX-202 is the only next generation gene therapy for Duchenne in a pivotal phase trial. The new data from the age 1-3 cohort builds on the favorable safety and efficacy profile seen in ages 4 and ...

Try it free for 7 days Regenxbio Inc RGNX revealed on Wednesday new interim data from two additional patients in the Phase 1/2 portion of the AFFINITY DUCHENNE trial of RGX-202, an ...